丁型肝炎治疗:未被满足的医疗需求
本文综述慢性丁型肝炎(CHD)新疗法的研究进展,指出目前仍以干扰素α为基础且疗效有限。三种新策略在评估中:Myrcludex B阻断病毒入肝细胞,Lonafarnib抑制病毒形态发生,REP 2139阻止成熟病毒输出。Myrcludex B和Lonafarnib与聚乙二醇干扰素α联用可提高疗效,REP 2139联用在一项12例试点研究中使约半数患者血清HDV RNA和HBsAg清除。长期治疗耐受性成为问题,需确认REP 2139初步数据。
要点
- 慢性丁型肝炎现有干扰素α疗法疗效有限,急需新药。
- Myrcludex B和Lonafarnib与Peg-IFNα联用可提高疗效。
- REP 2139联合Peg-IFNα在12例试点中约半数清除HDV RNA和HBsAg。
核心结论
- 慢性丁型肝炎治疗仍以干扰素α为基础,疗效有限,新疗法是迫切医疗需求。
研究设计与样本
- 本文为对新近发表医学文献的综述,未报告系统检索范围或样本量。
主要发现
- Myrcludex B和Lonafarnib与Peg-IFNα联用可提高治疗疗效。
- 一项试点研究中,REP 2139联合Peg-IFNα使约半数(12例中)患者血清HDV RNA和HBsAg清除。
关键数值与推荐
- Myrcludex B为HBsAg pre-S1结构域肉豆蔻酰化脂肽,阻断HDV进入肝细胞。
- Lonafarnib为宿主法尼基转移酶抑制剂,阻止大HD抗原法尼基化而妨碍病毒形态发生。
- REP 2139为核酸聚合物,推测通过抑制亚病毒HBsAg颗粒合成阻止成熟HDV输出。
临床怎么用
- Myrcludex B或Lonafarnib需与Peg-IFNα联用长期治疗以实现临床控制。
- 长期治疗耐受性问题需关注,正在研究Peg-IFNλ是否耐受性更好。
- REP 2139联合Peg-IFNα的初步数据需进一步确认。
局限性
- REP 2139联合Peg-IFNα的清除数据来自12例试点研究,需确认原始结果。
- 长期治疗耐受性成为问题。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Therapy of chronic hepatitis D (CHD) is still based on interferon alpha (IFNα), introduced in clinical practice 30 years ago: results are modest and better therapies are an urgent medical need. AIMS: This article provides a critical overview of the new therapies under investigation for CHD. SOURCES: Review of the recently published medical literature. CONTENT: New therapeutic efforts aim to deprive the hepatitis D virus (HDV) of functions provided to its life cycle by the hepatitis B Virus (HBV) or by the host. Three therapeutic strategies are in evaluation: a) Myrcludex B, a myristolated lipopeptide of the pre-S1 domain of the HBsAg that blocks the entry of the HDV into hepatocyes and controls infection by preventing the spreading of the virus to liver cells not infected by the HBV; b) Lonafarnib, an inhibitor of a host farnesyl-transferase that hinders morphogenesis of the HDV by preventing the farnesylation of the large HD-antigen, necessary for virion assembly; c) REP 2139, a nucleic acid polymer that prevents export of the mature HDV by the presumed inhibition of the synthesis of subviral HBsAg particles with which the virion is coated. Myrcludex B and Lonafarnib increase therapeutic efficacy in combination with Peg-IFNα. In a pilot study, REP 2139 in combination with Peg-IFNα induced the clearance of serum HDV RNA and of the HBsAg in about half of 12 treated patients. IMPLICATIONS: Long-term therapies with either Myrcludex B or Lonafarnib in combination with Peg-IFNα are required to achieve clinical control of CHD. However, with prolonged therapies tolerance becomes a problem; studies are on the way to determine whether Peg-IFN lambda may be better tolerated that Peg-IFNα. The promising preliminary data of REP 2139 in combination with Peg-IFNα await confirmation of the original pilot study.
引用
- Caviglia GP, Rizzetto M. Treatment of hepatitis D: an unmet medical need. Clin Microbiol Infect. 2020. PMID: 32120043. doi:10.1016/j.cmi.2020.02.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。